Vital sign changes in use of prilocaine and mepivacaine
Phase 2
- Conditions
- controlled hypertensive patients.
- Registration Number
- IRCT20200707048045N1
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
Patients with controlled hypertension who are willing to cooperate
Exclusion Criteria
Patients with a history of drug allergy, a history of asthma, nasal polyps, bronchospasm or angioedema,
heart failure or liver failure,
pregnancy,
patients with idiopathic or congenital methemoglobinemia,
patients with bleeding disorders,
patients taking anticoagulant drugs
failure to sign a written consent
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Heart rate. Timepoint: Before intervention and 10 , 30 minute after. Method of measurement: Pulse oximeter.;Blood pressure. Timepoint: Before intervention and 10 , 30 minute after. Method of measurement: Blood pressure monitor.;Blood oxygen saturation. Timepoint: Before intervention and 10 , 30 minute after. Method of measurement: Pulse oximeter.
- Secondary Outcome Measures
Name Time Method Stress score. Timepoint: before and after intervention. Method of measurement: questionnaire.